23 Jul Outpace Bio
Outpace is using unrivaled AI-powered protein design to deliver on the promise of cell therapy for solid tumors by programming cells for improved function inside the patient. The company designs proteins that solve the key barriers to efficacy: poor access to the tumor, weak survival, rapid inactivation, antigen escape, and high required doses that drive toxicity. Outpace creates modular, plug-and-play technology assets and combines them to produce cell therapies with unprecedented efficacy, advancing an internal pipeline of engineered T cell therapies for solid tumors. Lead program OPB-101, a mesothelin-specific CAR T cell therapeutic, demonstrates complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track to enter the clinic in 2025. Outpace’s approach to internal and partnered pipeline development is optimized for rapid clinical validation of its technologies across diverse cell types, manufacturing processes, and disease indications. Outpace is based in Seattle, Washington.
